{"pmid":32439197,"title":"COVID-19 and Multiorgan Response.","text":["COVID-19 and Multiorgan Response.","Since the outbreak and rapid spread of COVID-19 starting late December 2019, it has been apparent that disease prognosis has largely been influenced by multiorgan involvement. Comorbidities such as cardiovascular diseases have been the most common risk factors for severity and mortality. The hyperinflammatory response of the body, coupled with the plausible direct effects of severe acute respiratory syndrome on body-wide organs via angiotensin-converting enzyme 2, has been associated with complications of the disease. Acute respiratory distress syndrome, heart failure, renal failure, liver damage, shock, and multiorgan failure have precipitated death. Acknowledging the comorbidities and potential organ injuries throughout the course of COVID-19 is therefore crucial in the clinical management of patients. This paper aims to add onto the ever-emerging landscape of medical knowledge on COVID-19, encapsulating its multiorgan impact.","Curr Probl Cardiol","Zaim, Sevim","Chong, Jun Heng","Sankaranarayanan, Vissagan","Harky, Amer","32439197"],"abstract":["Since the outbreak and rapid spread of COVID-19 starting late December 2019, it has been apparent that disease prognosis has largely been influenced by multiorgan involvement. Comorbidities such as cardiovascular diseases have been the most common risk factors for severity and mortality. The hyperinflammatory response of the body, coupled with the plausible direct effects of severe acute respiratory syndrome on body-wide organs via angiotensin-converting enzyme 2, has been associated with complications of the disease. Acute respiratory distress syndrome, heart failure, renal failure, liver damage, shock, and multiorgan failure have precipitated death. Acknowledging the comorbidities and potential organ injuries throughout the course of COVID-19 is therefore crucial in the clinical management of patients. This paper aims to add onto the ever-emerging landscape of medical knowledge on COVID-19, encapsulating its multiorgan impact."],"journal":"Curr Probl Cardiol","authors":["Zaim, Sevim","Chong, Jun Heng","Sankaranarayanan, Vissagan","Harky, Amer"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439197","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cpcardiol.2020.100618","locations":["multiorgan","multiorgan","multiorgan"],"topics":["Mechanism","Diagnosis","Treatment"],"weight":1,"_version_":1667523504735518721,"score":9.490897,"similar":[{"pmid":32358232,"title":"Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIO-A \"Living Working Document\".","text":["Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIO-A \"Living Working Document\".","The severe acute respiratory syndrome (SARS)-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 (COVID)-19 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of COVID-19; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from ASAIO. Of note, this is a \"living document,\" which will be updated periodically, as additional information and understanding emerges.","ASAIO J","Rajagopal, Keshava","Keller, Steven P","Akkanti, Bindu","Bime, Christian","Loyalka, Pranav","Cheema, Faisal H","Zwischenberger, Joseph B","El Banayosy, Aly","Pappalardo, Federico","Slaughter, Mark S","Slepian, Marvin J","32358232"],"abstract":["The severe acute respiratory syndrome (SARS)-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 (COVID)-19 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of COVID-19; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from ASAIO. Of note, this is a \"living document,\" which will be updated periodically, as additional information and understanding emerges."],"journal":"ASAIO J","authors":["Rajagopal, Keshava","Keller, Steven P","Akkanti, Bindu","Bime, Christian","Loyalka, Pranav","Cheema, Faisal H","Zwischenberger, Joseph B","El Banayosy, Aly","Pappalardo, Federico","Slaughter, Mark S","Slepian, Marvin J"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358232","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1097/MAT.0000000000001180","topics":["Mechanism","Diagnosis","Treatment"],"weight":1,"_version_":1666138495323734016,"score":181.54604},{"pmid":32461141,"title":"The case of Complement activation in COVID-19 multiorgan impact.","text":["The case of Complement activation in COVID-19 multiorgan impact.","The novel coronavirus disease COVID-19 originates in the lungs, but may extend to other organs, causing, in severe cases, multiorgan damage, including cardiac injury and acute kidney injury. In severe cases, the presence of kidney injury is associated with increased risk of death, highlighting the relevance of this organ as a target of SARS-CoV-2 infection. COVID-19-associated tissue injury is not primarily mediated by viral infection, but rather is a result of the inflammatory host immune response, which drives hypercytokinemia and aggressive inflammation that affect lung parenchymal cells, diminishing oxygen uptake but also endothelial cells, resulting in endotheliitis and thrombotic events and intravascular coagulation. The complement system represents the first response of the host immune system to SARS-CoV-2 infection, but there is growing evidence that unrestrained activation of complement induced by the virus in the lungs and other organs plays a major role in acute and chronic inflammation, endothelial cell dysfunction, thrombus formation and intravascular coagulation, and ultimately contributes to multiple organ failure and death. In this review we will discuss the relative role of the different complement activation products in the pathogenesis of COVID-19-associated tissue inflammation and thrombosis and propose the hypothesis that blockade of the terminal complement pathway may represent a potential therapeutic option for the prevention and treatment of lung and multi-organ damage.","Kidney Int","Noris, Marina","Benigni, Ariela","Remuzzi, Giuseppe","32461141"],"abstract":["The novel coronavirus disease COVID-19 originates in the lungs, but may extend to other organs, causing, in severe cases, multiorgan damage, including cardiac injury and acute kidney injury. In severe cases, the presence of kidney injury is associated with increased risk of death, highlighting the relevance of this organ as a target of SARS-CoV-2 infection. COVID-19-associated tissue injury is not primarily mediated by viral infection, but rather is a result of the inflammatory host immune response, which drives hypercytokinemia and aggressive inflammation that affect lung parenchymal cells, diminishing oxygen uptake but also endothelial cells, resulting in endotheliitis and thrombotic events and intravascular coagulation. The complement system represents the first response of the host immune system to SARS-CoV-2 infection, but there is growing evidence that unrestrained activation of complement induced by the virus in the lungs and other organs plays a major role in acute and chronic inflammation, endothelial cell dysfunction, thrombus formation and intravascular coagulation, and ultimately contributes to multiple organ failure and death. In this review we will discuss the relative role of the different complement activation products in the pathogenesis of COVID-19-associated tissue inflammation and thrombosis and propose the hypothesis that blockade of the terminal complement pathway may represent a potential therapeutic option for the prevention and treatment of lung and multi-organ damage."],"journal":"Kidney Int","authors":["Noris, Marina","Benigni, Ariela","Remuzzi, Giuseppe"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461141","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.kint.2020.05.013","keywords":["c5 inhibition","covid-19","complement activation","complement terminal pathway","kidney injury","vascular injury"],"locations":["multiorgan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668079521362870273,"score":181.05759},{"pmid":32317203,"pmcid":"PMC7165109","title":"Cardiovascular complications in COVID-19.","text":["Cardiovascular complications in COVID-19.","BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19.","Am J Emerg Med","Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael","32317203"],"abstract":["BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19."],"journal":"Am J Emerg Med","authors":["Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317203","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ajem.2020.04.048","keywords":["acute myocardial infarction","covid-19","cardiovascular","dysrhythmia","heart failure","infectious disease","myocarditis","troponin"],"topics":["Treatment"],"weight":1,"_version_":1666138493618749441,"score":180.59192},{"pmid":32264666,"title":"Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon","text":["Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon","As it is known, we are all in a pandemic situation due to a novel coronavirus, officially named \"Severe Acute Respiratory Syndrome Coronavirus 2\" and the disease caused by the virus named \"Coronavirus disease-2019\". The virus seems to has propensity to infect older male individuals with underlying disease. The clinical features were on a large scale that varies from being an asymptomatic carrier to acute respiratory distress syndrome and multiorgan dysfunction. Fever, dry cough and fatigue are the most common symptoms. Not only, the disease seems to be rare and have a milder course in pediatric age but also respiratory failure, multiorgan dysfunction, and death are extremely rare. Although several comorbidities such as hypertension, diabetes and cardiovascular diseases are defined as a risk factor for developing the acute respiratory syndrome and need for intensive care; immune-compromised situations such as rheumatic disease which require immunosuppressive treatment strikingly are not found to be a risk factor for more severe disease course. However, there is a lack of data regarding the effects of \"Coronavirus disease-2019\" on pediatric patients with rheumatic diseases. Additionally, there are three controversial circumstances that patients with rheumatic diseases are believed to be more likely to have viral infections like \"Severe Acute Respiratory Syndrome Coronavirus 2\", on the other hand, antirheumatic drugs may have a protective and therapeutic role in Coronavirus disease-2019 and children are more unlikely to have serious disease course. Therefore, we aimed to have a contributor role for explaining this conundrum and present a bird's eye view regarding this equivocal issue in this review.","Balkan Med J","Haslak, Fatih","Yildiz, Mehmet","Adrovic, Amra","Barut, Kenan","Kasapcopur, Ozgur","32264666"],"abstract":["As it is known, we are all in a pandemic situation due to a novel coronavirus, officially named \"Severe Acute Respiratory Syndrome Coronavirus 2\" and the disease caused by the virus named \"Coronavirus disease-2019\". The virus seems to has propensity to infect older male individuals with underlying disease. The clinical features were on a large scale that varies from being an asymptomatic carrier to acute respiratory distress syndrome and multiorgan dysfunction. Fever, dry cough and fatigue are the most common symptoms. Not only, the disease seems to be rare and have a milder course in pediatric age but also respiratory failure, multiorgan dysfunction, and death are extremely rare. Although several comorbidities such as hypertension, diabetes and cardiovascular diseases are defined as a risk factor for developing the acute respiratory syndrome and need for intensive care; immune-compromised situations such as rheumatic disease which require immunosuppressive treatment strikingly are not found to be a risk factor for more severe disease course. However, there is a lack of data regarding the effects of \"Coronavirus disease-2019\" on pediatric patients with rheumatic diseases. Additionally, there are three controversial circumstances that patients with rheumatic diseases are believed to be more likely to have viral infections like \"Severe Acute Respiratory Syndrome Coronavirus 2\", on the other hand, antirheumatic drugs may have a protective and therapeutic role in Coronavirus disease-2019 and children are more unlikely to have serious disease course. Therefore, we aimed to have a contributor role for explaining this conundrum and present a bird's eye view regarding this equivocal issue in this review."],"journal":"Balkan Med J","authors":["Haslak, Fatih","Yildiz, Mehmet","Adrovic, Amra","Barut, Kenan","Kasapcopur, Ozgur"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32264666","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.4274/balkanmedj.galenos.2020.2020.4.43","keywords":["covid-19","sars virus","hydroxychloroquine","pediatrics","rheumatology","tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666138491941027841,"score":170.80002},{"pmid":32458400,"pmcid":"PMC7250255","title":"Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.","text":["Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.","COVID-19 is a syndrome that includes more than just isolated respiratory disease, as severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) also interacts with the cardiovascular, nervous, renal, and immune system at multiple levels, increasing morbidity in patients with underlying cardiometabolic conditions and inducing myocardial injury or dysfunction. Emerging evidence suggests that patients with the highest rate of morbidity and mortality following SARS-CoV2 infection have also developed a hyperinflammatory syndrome (also termed cytokine release syndrome). We lay out the potential contribution of a dysfunction in autonomic tone to the cytokine release syndrome and related multiorgan damage in COVID-19. We hypothesize that a cholinergic anti-inflammatory pathway could be targeted as a therapeutic avenue. Graphical Abstract .","J Cardiovasc Transl Res","Fudim, Marat","Qadri, Yawar J","Ghadimi, Kamrouz","MacLeod, David B","Molinger, Jeroen","Piccini, Jonathan P","Whittle, John","Wischmeyer, Paul E","Patel, Manesh R","Ulloa, Luis","32458400"],"abstract":["COVID-19 is a syndrome that includes more than just isolated respiratory disease, as severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) also interacts with the cardiovascular, nervous, renal, and immune system at multiple levels, increasing morbidity in patients with underlying cardiometabolic conditions and inducing myocardial injury or dysfunction. Emerging evidence suggests that patients with the highest rate of morbidity and mortality following SARS-CoV2 infection have also developed a hyperinflammatory syndrome (also termed cytokine release syndrome). We lay out the potential contribution of a dysfunction in autonomic tone to the cytokine release syndrome and related multiorgan damage in COVID-19. We hypothesize that a cholinergic anti-inflammatory pathway could be targeted as a therapeutic avenue. Graphical Abstract ."],"journal":"J Cardiovasc Transl Res","authors":["Fudim, Marat","Qadri, Yawar J","Ghadimi, Kamrouz","MacLeod, David B","Molinger, Jeroen","Piccini, Jonathan P","Whittle, John","Wischmeyer, Paul E","Patel, Manesh R","Ulloa, Luis"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458400","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s12265-020-10031-6","keywords":["ace2","covid-19","sars-cov2","vagus","vagus nerve stimulation"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668141322664411136,"score":169.10216}]}